Allergy Therapeutics (LON:AGY) Stock Passes Below Two Hundred Day Moving Average - Here's Why

Key Points

• The stock dipped below its 200‑day moving average (GBX 10.37), trading as low as GBX 9 intraday before last trading at GBX 10.90 on a volume of 186,741 shares and showing an 8.9% move.
• Key fundamentals show a market capitalization of £690.25 million, a negative P/E of -11.24 and an extremely high debt‑to‑equity of 629.58, while analysts expect FY EPS of -2.56.
• Allergy Therapeutics is an international biotech focused on allergy immunotherapy with aluminium‑free vaccines and a pipeline that includes grass, tree and house dust mite vaccines plus a preclinical peanut vaccine.

Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 10.37 and traded as low as GBX 9. Allergy Therapeutics shares last traded at GBX 10.90, with a volume of 186,741 shares trading hands.

Allergy Therapeutics Stock Up 8.9%

The company has a 50-day moving average of GBX 10.74 and a 200-day moving average of GBX 10.37. The company has a market capitalization of £690.25 million, a price-to-earnings ratio of -11.24, a price-to-earnings-growth ratio of -30.70 and a beta of 0.91. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. The business had revenue of GBX 3,628 million for the quarter. On average, equities analysts predict that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.